2019 a 'transformative year' for pharma M&A. Is that a good thing?
Big Pharma keeps getting bigger.
Fueled by the mega-mergers between Bristol-Myers Squibb and Celgene and between Allergan and AbbVie, the industry last year saw $350 billion worth of M&A, according to the new year-end report from the consultants at PwC. That’s a more than 50% increase on 2018.
“I kind of look at 2019 as a transformational year,” report author Glen Hunzinger told Endpoints News.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters